The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

FDA 因此于 2023 年 6 月批准秋水仙碱（0.5 mg/d）用于降低已确诊 ASCVD 或具有多种心血管疾病危险因素的成年患者的心肌梗死、卒中、冠状动脉血运重建、心血管死亡的风险。同时，秋水仙碱纳入欧洲心脏病学会（ESC）2024 ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

Scientists at St. Jude Children's Research Hospital have designed new drug frameworks that selectively target CYP3A4, one of the most critical CYP proteins. Structural insights from this work offer a ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for VITRAKVI® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric ...